(0.34%) 5 117.10 points
(0.33%) 38 366 points
(0.38%) 15 988 points
(-0.95%) $83.05
(5.56%) $2.03
(0.35%) $2 355.30
(0.46%) $27.66
(4.06%) $959.55
(-0.26%) $0.932
(-0.43%) $10.98
(-0.57%) $0.796
(1.69%) $93.43
@ $9.81
発行日: 15 2月 2024 @ 04:26
リターン: -6.68%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: 1.82 %
Live Chart Being Loaded With Signals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B...
Stats | |
---|---|
本日の出来高 | 68 595.00 |
平均出来高 | 407 914 |
時価総額 | 903.79M |
EPS | $-0.400 ( 2023-11-13 ) |
次の収益日 | ( $-0.410 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.83 |
ATR14 | $0.0260 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Chao David M | Sell | 10 385 | Ordinary Shares |
2024-03-31 | Weinhoff Gregory M | Sell | 11 742 | Ordinary Shares |
2024-03-31 | Saha Saurabh | Sell | 36 263 | Ordinary Shares |
2024-03-31 | Hussain Iqbal J | Sell | 7 520 | Ordinary Shares |
2024-03-31 | Bush Tia L | Sell | 6 419 | Ordinary Shares |
INSIDER POWER |
---|
61.95 |
Last 100 transactions |
Buy: 3 998 584 | Sell: 832 725 |
ボリューム 相関
Centessa Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
HYRE | -0.907 |
VIVE | -0.903 |
TLGT | -0.89 |
QTEK | -0.881 |
BVXV | -0.879 |
BHTG | -0.876 |
ONEM | -0.874 |
TRMT | -0.873 |
JG | -0.862 |
SVVC | -0.859 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Centessa Pharmaceuticals 相関 - 通貨/商品
Centessa Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $6.88M |
総利益: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2023 |
収益: | $6.88M |
総利益: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2022 |
収益: | $0 |
総利益: | $-130 919 (0.00 %) |
EPS: | $-2.31 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-4.05 |
Financial Reports:
No articles found.
Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。